Babesia Microti DNA Test

If you have ever been bitten by a tick in the northeastern or upper midwestern United States, there is a parasite your doctor almost certainly did not test for. Babesia microti is a microscopic organism that invades your red blood cells, multiplies inside them, and eventually ruptures them, causing a condition called babesiosis. Standard bloodwork, including a complete blood count, will not identify it. Even a dedicated Lyme disease panel will miss it entirely. The only way to know whether this parasite is in your blood is to test for its DNA directly.

This test uses a technique called PCR (polymerase chain reaction), which amplifies tiny traces of the parasite's genetic material so they can be detected. A positive result means the parasite's DNA is present in your blood, indicating active or recent infection. A negative result means no parasite DNA was found. Unlike many biomarkers that exist on a spectrum from low to high, this is fundamentally a yes-or-no test: either the parasite is there or it is not.

What Babesia Microti Does to Your Body

Babesia microti (B. microti) is a single-celled parasite in the same biological group as the parasite that causes malaria. It is transmitted primarily through the bite of the black-legged tick (Ixodes scapularis), the same tick that carries Lyme disease. Once in your bloodstream, the parasite enters red blood cells, reproduces by splitting into four daughter organisms (forming a distinctive shape called a "Maltese cross" under the microscope), and then bursts out to infect more cells.

This cycle of invasion and destruction is what causes symptoms. Your body loses red blood cells faster than it can replace them, a process called hemolytic anemia (anemia caused by red blood cell breakdown rather than blood loss). The debris from ruptured cells triggers inflammation throughout your body. Symptoms typically appear one to four weeks after a tick bite and include fever, chills, sweating, fatigue, headache, and muscle aches.

Why PCR Testing Matters

The traditional way to diagnose babesiosis is to look at a blood smear under a microscope and search for parasites inside red blood cells. This works well when the infection is advanced and many cells are infected, but it has real limitations. The parasites are tiny, and when only a small percentage of your red blood cells are infected, a technician can easily miss them. PCR testing is more sensitive than blood smear examination, particularly when parasite levels are low or early in infection when organisms are difficult to see.

PCR also has an advantage over antibody testing. Babesia antibody tests measure your immune system's response to the parasite rather than detecting the parasite itself. The problem is that antibodies can remain in your blood for a year or more after the infection has cleared, making it impossible to tell whether you have an active infection or simply had one in the past. The Infectious Diseases Society of America (IDSA) specifically recommends blood smear or PCR, not antibody testing, for confirming acute babesiosis.

Severity and Complications

Many people with babesiosis recover fully with appropriate treatment. But the disease is not always mild. About half of all reported cases require hospitalization, and roughly one-third of patients develop complications. These can include acute respiratory distress syndrome (severe lung failure), disseminated intravascular coagulation (widespread abnormal blood clotting), kidney failure, and shock.

Cardiac complications are more common than many clinicians expect. In a study of 163 hospitalized patients, 19.6% developed heart-related problems, and mortality was higher in this group. A separate large analysis of 1,566 PCR-confirmed babesiosis patients found that 10.2% developed sepsis (a life-threatening whole-body response to infection), with significantly higher mortality at 30 days, 90 days, and one year compared to those who did not develop sepsis.

Who Is at Greatest Risk

Certain groups face dramatically higher risk of severe babesiosis. People without a functioning spleen (asplenic individuals) are at the top of this list, because the spleen plays a key role in filtering infected red blood cells from the bloodstream. Others at elevated risk include people over age 50, those with weakened immune systems (particularly people with B-cell lymphoma, those taking the drug rituximab, or people with HIV/AIDS), patients with heart or kidney disease, and newborns.

Babesiosis is also one of the most common infections transmitted through blood transfusions in the United States. Transfusion-transmitted babesiosis is especially dangerous, causing death in approximately 20% of infected blood recipients. Since 2019, the FDA has recommended year-round screening of blood donations in 14 endemic states using DNA-based testing.

The Coinfection Problem

Because the same tick that transmits B. microti also carries the bacteria responsible for Lyme disease and anaplasmosis, coinfection is common. About 10% of patients diagnosed with early Lyme disease are simultaneously infected with B. microti, and roughly half of babesiosis patients also test positive for Lyme disease. This matters because the antibiotics used to treat Lyme disease do not work against Babesia. If you are being treated for Lyme disease and not improving as expected, an undiagnosed Babesia coinfection may be the reason.

Where Babesiosis Is Found

Babesiosis is concentrated in the northeastern and upper midwestern United States. The states with the highest incidence include Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, and Vermont. Several of these states have seen dramatic increases in recent years: Maine, New Hampshire, and Vermont experienced case increases ranging from 372% to 1,602% between 2011 and 2019. The geographic range is expanding.

That said, transfusion-transmitted cases can occur anywhere in the country, at any time of year, with incubation periods up to six months. If you received a blood transfusion and develop unexplained fever, fatigue, and signs of red blood cell destruction within the following months, babesiosis should be considered regardless of where you live.

Interpreting Your Results

This test is qualitative: the result is either "detected" (positive) or "not detected" (negative). There are no optimal ranges, risk tiers, or gray zones to interpret. Any detectable parasite DNA in your blood is abnormal. The only healthy result is a negative one.

When the infection is present, disease severity is assessed separately using the percentage of red blood cells that are infected (parasitemia), measured by blood smear microscopy. Higher parasitemia correlates with more severe disease, particularly in immunocompromised patients. Your doctor will also look at supporting lab findings: low red blood cell count (anemia), low platelet count (thrombocytopenia), elevated liver enzymes (AST, ALT, alkaline phosphatase), and signs of red blood cell destruction, including elevated LDH (lactate dehydrogenase, an enzyme released from damaged cells), elevated bilirubin (a breakdown product of hemoglobin), and reduced haptoglobin (a protein that binds free hemoglobin; low levels indicate red blood cells are being destroyed faster than normal).

When Results Can Be Misleading

The most important thing to know about this test is that a positive result does not always mean you need treatment. B. microti DNA can persist in the blood for weeks to months after successful treatment, and even longer if you were never treated but your immune system controlled the infection on its own. In one study, parasite DNA persisted for an average of 82 days in untreated but asymptomatic individuals, compared to 16 days in treated patients. A positive PCR result during or after treatment does not necessarily mean the treatment failed. It may simply mean residual genetic material is still being cleared.

For this reason, the IDSA recommends against using PCR to routinely monitor treatment response in people with healthy immune systems. Blood smear microscopy, which detects intact living parasites rather than free-floating DNA fragments, is a better tool for tracking whether treatment is working. PCR is most useful for the initial diagnosis, not for follow-up.

Sample handling can also affect results. Blood samples collected in EDTA tubes should be processed promptly, and prolonged storage at room temperature can affect test accuracy. Hemolysis (red blood cell breakdown during sample collection or transport) and lipemia (excess fat in the blood sample) can also interfere with molecular testing.

Tracking Over Time

For most people, this is not a test you track serially the way you would cholesterol or blood sugar. If you test negative and have no symptoms or ongoing tick exposure, a single negative result is reassuring. If you test positive and receive treatment, your clinician will use blood smears rather than PCR to monitor parasite clearance, because PCR can stay positive long after the infection is gone.

The exception is immunocompromised patients. If you are taking immunosuppressive medications, have had your spleen removed, or have conditions that weaken your immune system, babesiosis can relapse. In these cases, treatment is extended to at least six weeks (including two final weeks with negative blood smears), and closer monitoring is warranted. If blood smears become negative but symptoms persist, PCR testing can help determine whether low-level parasitemia is still present.

If you live in or travel to an endemic area and have ongoing tick exposure, periodic testing during or after tick season makes sense as a screening measure, particularly if you develop unexplained fever, fatigue, or signs of anemia. Getting a baseline understanding of your status after a known tick bite, and retesting if symptoms develop, is the most practical approach for a prevention-minded individual.